These 52-week data reinforce HTD1801's potential as a truly differentiated therapeutic to concurrently address metabolic ...

The U.S. FDA has granted orphan drug designation to Dewpoint Therapeutics Inc.’s DPTX-3186, its first-in-class condensate ...

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...

IND opening marks culmination of partnership between Dewpoint and Evotec, advancing a de novo development candidate through ...

Santec AOC Corporation won the Vico Cup for 'Best Laser Industry Application' with the SLM-310, advancing precision in laser ...

The ODD programme incentivises the development of medicines for conditions affecting fewer than 200,000 individuals in the US ...

Dewpoint Therapeutics Inc. has announced an IND in the U.S. for DPTX-3186, a first-in-class oral condensate modulator ...

Topline results were announced from a phase 3 trial evaluating BNC210 in patients with social anxiety disorder.

Researchers have developed a new technology that can shape the spectrum of light emitted from a laser frequency comb across ...

Follicle-stimulating hormone (FSH), a glycoprotein secreted by gonadotroph cells of the anterior pituitary, is classically ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DPTX3186, an investigational therapy being ...

These 52-week data reinforce HTD1801's potential as a truly differentiated therapeutic to concurrently address metabolic dysregulation, inflammation, and renal progression in type 2 diabetes mellitusH ...